ULBI - Earnings announcements

NEWARK, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the fourth quarter and full year ended December 31, 2025 as follows: Fourth Quarter: Sales of $48.5 million compared to $43.9 million for the 2024 fourth quarterGross profit of $12.1 million, or 24.9% of revenue, compared to $10.6 million, or 24.2% of revenue, for the 2024 fourth quarterOperating (loss) income of ($10.6) million, which includes a ($12.2) million intangible asset impairment charge and ($1.2) million of one-time costs, compared to $1.5 million for the 2024 fourth quarterGAAP EPS of ($0.45), which includes ($0.57) for the intangible asset impairment charge net

NEWARK, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ending December 31, 2025 before the market opens on Tuesday, March 10, 2026. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on March 10, 2026. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BIf9df949a927a4356820e8cfb1becccdc.

NEWARK, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2025 with the following results: Sales of $43.4 million increased 21.5% from $35.7 million for the third quarter of 2024; excluding Electrochem, sales of $36.6 million increased 2.5%Gross profit of $9.6 million, or 22.2% of revenue, compared to $8.7 million, or 24.3% of revenue, for the third quarter of 2024Operating loss of $1.0 million, reflecting one-time non-recurring costs of $1.1 million, including a $.5 million provision to close our Calgary facility, compared to operating income of $0.5 million for the third quarter of 2024GAAP EP

NEWARK, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2025 before the market opens on Tuesday, November 18, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 18, 2025.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call:   https://register-conf.media-server.com/register/BI0301fd92021249ef830e0c9c7b

NEWARK, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2025 with the following results: Sales of $48.6 million increased 13.0% from $43.0 million for the second quarter of 2024; excluding Electrochem, sales of $39.3 million declined 8.7% due to a 57.2% decrease in Communications Systems salesGross profit of $11.6 million, or 23.9% of revenue, compared to $11.6 million, or 26.9% of revenue, for the second quarter of 2024Operating income of $2.3 million, including one-time non-recurring costs and purchase accounting adjustments of $0.3 million, compared to $3.9 million for the second quarter of 202

NEWARK, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2025 before the market opens on Thursday, August 7, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at Noon ET on August 7, 2025. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BIbda86e3ea7b342b6944287e49c2d3e9c. Th

NEWARK, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights: Sales of $50.7 million compared to $41.9 million for the 2024 first quarter, including a 32.4% increase for Batteries & Energy Products and a 36.2% decrease in Communications Systems salesGross profit of $12.7 million, or 25.1% of revenue, compared to $11.5 million, or 27.4% of revenue, for the 2024 first quarterOperating income of $3.4 million, including one-time non-recurring costs and purchase accounting adjustments of $0.4 million, compared to $4.1 million for the 2024 first quarterGAAP EPS of $0.11 comp

NEWARK, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2025 before the market opens on Friday, May 9, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at 10:00 AM ET on May 9, 2025. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BI00ee37974c5b4cbc86cd1d7ef099d998. This will e

Acquisition of Electrochem Completed and Integration Has Commenced                 NEWARK, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:   ULBI) reported operating results for the fourth quarter and full year ended December 31, 2024 as follows: Fourth Quarter: Sales of $43.9 million compared to $44.5 million for the 2023 fourth quarter, including a 11.7% increase in Battery & Energy Products sales and a 55.1% decrease in Communications Systems salesGross profit of $10.6 million, or 24.2% of revenue, compared to $11.4 million, or 25.6% of revenue, for the 2023 fourth quarterOperating income of $1.5 million, including one-time costs and GAAP adjustments of

NEWARK, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ending December 31, 2024 before the market opens on Tuesday, April 1, 2025. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 1, 2025.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call:   https://register-conf.media-server.com/register/BI1a1f31c093654241b376ab0dfc2c088b

NEWARK, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI), today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The extension is necessary to allow for the completion of the accounting close and financial results audit of Electrochem Solutions, Inc., which the Company acquired on October 31, 2024. The Company expects to file its Form 10-K with the Securities and Exchange Commission as soon as practicable, and no later than April 1, 2025, in accordance with Rule 12b-25. In addition, the Company will r

NEWARK, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ending December 31, 2024 before the market opens on Tuesday, March 11, 2025. Due to the time required to complete the accounting close and audit of the financial results of Electrochem Solutions, Inc., which the Company acquired on October 31, 2024, Ultralife is reporting fourth quarter results later than it has in the past, in contrast to its established practice of reporting fourth quarter results on the Thursday of the sixth week after year end. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET o

NEWARK, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2024 as follows: Sales of $35.7 million compared to $39.5 million for the 2023 third quarter, including 1.9% growth in Battery & Energy Products sales and a 58.2% decrease in Communications Systems salesGross profit of $8.7 million, or 24.3% of revenue, compared to $9.8 million, or 24.8% of revenue, for the 2023 third quarterOperating income of $0.5 million, including legal fees and other costs of $0.3 million directly related to the acquisition of Electrochem Solution, Inc., compared to $2.1 for the 2023 third quarterGAAP EPS of $0.02 co

NEWARK, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2024 before the market opens on Friday, November 8, 2024. The Company is reporting third quarter results later than its customary date after its quarter end in order to accommodate the expected closing of its acquisition of Electrochem Solutions, Inc. by the end of October. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 8, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable

NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to

NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin

NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of $0.02 for the 2023 first quarterAdjusted EBITDA of $5.2 million, a four-fold gain compared to $1.2 million last yearBacklog of $97.4 million exiting the 202

NEWARK, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2024 before the market opens on Thursday, April 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI5d712724df6d4c65bb6496c4ce2d606f. This will elimi

NEWARK, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) --  Ultralife Corporation (NASDAQ:   ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: Sales of $44.5 million representing a 23.4% year-over-year increaseHighest medical sales quarter in Company's historyOperating income of $3.6 million versus $0.2 million for the 2022 fourth quarterAdjusted EPS of $0.18 compared to a loss of $0.03 for the 2022 fourth quarterAdjusted EBITDA of $4.8 million representing a 134.8% year-over-year increaseBacklog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: Sales of $158.6 million

NEWARK, N.Y., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ended December 31, 2023 before the market opens on Thursday, February 15, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on February 15, 2024.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI9f2b6fae66954f53b4517cbe89148738. This

NEWARK, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights: Sales of $39.5 million representing an 18.8% year-over-year increaseOperating income of $2.1 million versus a loss of $0.6 million for the 2022 third quarterAdjusted EPS of $0.10 compared to a loss of $0.03 for the 2022 third quarterAdjusted EBITDA of $3.5 million representing a 177.3% year-over-year increaseBacklog of $101.1 million exiting the 2023 third quarter "Driven by continuing strong demand from our government/defense and medical customers, sales grew 19% for both the 2023 third quarter and th

NEWARK, N.Y., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2023 before the market opens on Thursday, October 26, 2023. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on October 26, 2023. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI7f14d2264d2242c1adb217d21d75ab21. This wil

NEWARK, N.Y., July 27, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2023 with the following highlights: Sales of $42.7 million representing a 32.9% year-over-year increaseOperating income of $3.7 million compared to $0.8 million for the 2022 second quarterAdjusted EPS of $0.29 compared to $0.03 for the 2022 second quarterAdjusted EBITDA of $6.3 million or 14.7% of sales versus $2.2 million or 6.8% last yearBacklog increase to $110.9 million, the highest level in the Company's history "Driven by surging demand from our government/defense and medical customers, we delivered a 33% year-over-year sal

NEWARK, N.Y., July 13, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2023 before the market opens on Thursday, July 27, 2023. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 27, 2023.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI05d612e50dae4c4f91cf91687da98603. This will elimin

NEWARK, N.Y., April 27, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported breakeven operating income and adjusted EBITDA of $1.2 million on revenue of $31.9 million for the first quarter ended March 31, 2023. The operating results for the first quarter of 2023 were negatively impacted by the cybersecurity attack announced by the Company on March 2, 2023. For the first quarter of 2022, the Company reported an operating loss of $0.3 million and adjusted EBITDA of $1.1 million on revenue of $30.4 million. As disclosed on March 2, 2023, the Company discovered a cybersecurity ransomware attack at its Newark, NY and Virginia Beach, VA locations on January 25, 2023. The attac

NEWARK, N.Y., April 13, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2023 before the market opens on Thursday, April 27, 2023. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 27, 2023.   Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link: https://register.vevent.com/register/BId33ee3ac5fa74d2e946203064e7fb772 prior to the call. This will eli

NEWARK, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating profit of $0.2 million and adjusted EBITDA of $2.0 million on revenue of $36.1 million for the fourth quarter ended December 31, 2022. The operating results for the fourth quarter of 2022 include a one-time charge of $0.8 million for 2023 severance costs associated with the Company's former President & CEO, who, as announced on November 22, 2022, is no longer with the Company. For the fourth quarter of 2021, the Company reported an operating loss of $1.2 million and adjusted EBITDA of ($0.1) million on revenue of $23.8 million. "For the fourth quarter, we delivered a 220-basis point imp

NEWARK, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ended December 31, 2022 before the market opens on Thursday, March 2, 2023. We are reporting our quarterly results later than our customary reporting practice due to illnesses experienced by some members of our Accounting/Finance Team causing delays in the year-end closing and audit. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on March 2, 2023. Please see the new call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: Our investor conference call-in process has

NEWARK, N.Y., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported an operating loss of $0.6 million and adjusted EBITDA of $1.3 million on revenue of $33.2 million for the third quarter ended September 30, 2022. For the third quarter of 2021, the Company reported an operating loss of $0.8 million and adjusted EBITDA of $0.3 million on revenue of $21.8 million. "For the third quarter, government/defense revenue doubled year-over-year reflecting higher demand from our customers in Battery & Energy Products and shipments of larger awards in Communications Systems. This increase in government/defense revenue along with the addition of Excell, resulted in a 53% incre

NEWARK, N.Y., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2022, before the market opens on Thursday, October 27, 2022. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on October 27, 2022. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations Section of the Company's website at http://investor.ultralifecorporation.com. For those

NEWARK, N.Y., July 28, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating income of $0.8 million and Adjusted EBITDA of $2.2 million on revenue of $32.1 million for the second quarter ended June 30, 2022. For the second quarter of 2021, the Company reported operating income of $1.1 million and Adjusted EBITDA of $2.2 million on revenue of $26.8 million. "Driven by the Excell acquisition and strong shipments to core commercial end-markets, for the second quarter we delivered a 20% year-over-year sales increase and returned to total Company profitability. Persistent supply chain constraints continued to delay shipments against government/defense orders in both o

NEWARK, N.Y., July 14, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2022, before the market opens on Thursday, July 28, 2022. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 28, 2022. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations Section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot

NEWARK, N.Y., April 28, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported an operating loss of $0.3 million on revenue of $30.4 million for the first quarter ended March 31, 2022. For the first quarter of 2021, the Company reported operating income of $1.0 million on revenue of $26.0 million. "Strong order flow in commercial end-markets, particularly medical and oil & gas, along with a lift from recently acquired Excell Battery Group ("Excell"), more than offset supply chain constraints that continued to delay our government/defense revenues, resulting in a 16.9% increase in total Company revenue. Robust demand across the business boosted backlog at quarter end to appr

NEWARK, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2022, before the market opens on Thursday, April 28, 2022. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 28, 2022. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations Section of the Company's website at http://investor.ultralifecorporation.com. For those who can

NEWARK, N.Y., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ended December 31, 2021 before the market opens on Thursday, February 3, 2022. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on February 3, 2022. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations Section of the Company's website at http://investor.ultralifecorporation.com. For those who

NEWARK, N.Y., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported an operating loss of $0.8 million on revenue of $21.8 million for the third quarter ended September 30, 2021. For the third quarter of 2020, the Company reported operating income of $0.7 million on revenue of $24.4 million. "Supply chain bottlenecks intensified during the third quarter which extended both our own and our customers' product manufacturing schedules and delayed shipments, thereby impacting third quarter revenue and earnings. The 11% year-over-year decrease in revenue, primarily related to the government/defense sector, masked a 5% increase in commercial sales led by a continued

NEWARK, N.Y., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2021, before the market opens on Thursday, October 28, 2021. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on October 28, 2021. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations Section of the Company's website at http://investor.ultralifecorporation.com. For those